Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics is showing promising signs of growth with its recent financing activities and partnerships. However, its rising expenses due to mergers and acquisition consolidation is a potential concern. Despite revising estimates to reflect a higher share count, the company's market potential and favorable product positioning present potential for high rewards. The potential for growth through accretive acquisitions and backing from strategic investors also provide a strong catalyst for the stock. Risks to achieving the 12-month price target of $5.50 include expense control, dilution from financing, and regulatory approvals. Ascendiant Capital Markets, LLC has a Buy rating on the stock.

Vivos Therapeutics is facing challenges in their transition to a new distribution strategy, leading to a temporary increase in net loss. While the integration of Sleep Center Network is showing early promise with a significant uptick in revenue, there is uncertainty surrounding the company's gross margins and their ability to quickly reach cashflow breakeven as they expand. Additionally, their flexible partnership model with sleep centers may provide an alternative source of revenue, but it remains to be seen how successful this strategy will be.